



Mithra Announces Commercial Launch of Myring™ in the Netherlands

Liege, Belgium, 19 August 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces the commercial launch of its vaginal contraceptive ring Myring™ in the Netherlands.

Mithra's vaginal contraceptive ring will be distributed in the Netherlands by Novalon SA¹. With 315,000 vaginal rings sold per year, the Dutch contraceptive rings market is worth approximately EUR 2.75 million.

Earlier this month, Mithra announced the approval of the extension of the shelf life of Myring™ to 36 months by the European Authorities. The further prolongation of the previously announced shelf life extension from 18 to 24 months, including the removal of the requirement for special temperature storage, offer distributors, pharmacists and patients a more convenient option compared to competitor products.

François Fornieri, CEO Mithra Women's Health, comments: *"We are pleased to include the Netherlands amongst the six countries in which Myring™ is now commercialized. The Netherlands represents the fifth European commercial launch this year, in addition to Belgium, Luxembourg, Germany, and Austria, which underlines the efforts we have made in manufacturing and delivery during the unprecedented health crisis."*

For more information, please contact:

Alexandra Deschner (Investors) : +32 495 55 14 78 - investorrelations@mithra.com

Carole Kousis (Press) : +32 4 349 28 22 – press@mithra.com

About Myring™

Myring™ (etonogestrel/ethinyl estradiol vaginal ring) is a non-biodegradable, flexible, transparent, combination contraceptive vaginal ring, with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It is made of ethylene vinylacetate copolymers, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases, in line with the originator (Nuvaring®), on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. The ring is to remain in place continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed usually occurs. A new ring is inserted one week after the last ring was removed.

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to

¹ Novalon is a fully-owned subsidiary of Mithra, housing the asset Myring™.

develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment for perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 85 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

News Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)